- Home
- VYGR vs VBF Comparison
VYGR vs VBF Comparison
Compare VYGR & VBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- VBF
- Stock Information
- Founded
- VYGR 2013
- VBF 1970
- Country
- VYGR United States
- VBF United States
- Employees
- VYGR N/A
- VBF N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- VBF Trusts Except Educational Religious and Charitable
- Sector
- VYGR Health Care
- VBF Finance
- Exchange
- VYGR Nasdaq
- VBF Nasdaq
- Market Cap
- VYGR 165.5M
- VBF 175.4M
- IPO Year
- VYGR 2015
- VBF N/A
- Fundamental
- Price
- VYGR $2.74
- VBF $15.39
- Analyst Decision
- VYGR Strong Buy
- VBF
- Analyst Count
- VYGR 8
- VBF 0
- Target Price
- VYGR $14.33
- VBF N/A
- AVG Volume (30 Days)
- VYGR 377.3K
- VBF 45.5K
- Earning Date
- VYGR 05-06-2025
- VBF 01-01-0001
- Dividend Yield
- VYGR N/A
- VBF 5.18%
- EPS Growth
- VYGR N/A
- VBF N/A
- EPS
- VYGR N/A
- VBF N/A
- Revenue
- VYGR $66,958,000.00
- VBF N/A
- Revenue This Year
- VYGR N/A
- VBF N/A
- Revenue Next Year
- VYGR $45.34
- VBF N/A
- P/E Ratio
- VYGR N/A
- VBF N/A
- Revenue Growth
- VYGR N/A
- VBF N/A
- 52 Week Low
- VYGR $2.65
- VBF $13.68
- 52 Week High
- VYGR $9.55
- VBF $16.27
- Technical
- Relative Strength Index (RSI)
- VYGR 33.88
- VBF 53.85
- Support Level
- VYGR $2.71
- VBF $15.20
- Resistance Level
- VYGR $2.99
- VBF $15.43
- Average True Range (ATR)
- VYGR 0.18
- VBF 0.14
- MACD
- VYGR -0.05
- VBF -0.00
- Stochastic Oscillator
- VYGR 10.86
- VBF 59.38
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.